Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Mayo Clinic
ClinicalTrials.gov Identifier:
NCT01057225
First received: January 26, 2010
Last updated: September 26, 2016
Last verified: January 2016
  Purpose

RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Thalidomide may stop the growth of cancer cells by blocking blood flow to the tumor. Giving combination chemotherapy together with carfilzomib and thalidomide may kill more cancer cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of carfilzomib when given together with cyclophosphamide, thalidomide, and dexamethasone in treating patients with newly diagnosed active multiple myeloma.


Condition Intervention Phase
Multiple Myeloma
Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma
Drug: carfilzomib
Drug: cyclophosphamide
Drug: thalidomide
Drug: dexamethasone
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II Trial of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone (CYCLONE) in Patients With Newly Diagnosed Active Multiple Myeloma

Resource links provided by NLM:


Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • Maximum Tolerated Dose (Phase I) [ Time Frame: From baseline to end of active treatment, up to 12 28-day cycles. ] [ Designated as safety issue: Yes ]

    To establish the maximum tolerated dose of carfilzomib given in combination with oral cyclophosphamide and thalidomide and dexamethasone.

    For this protocol, dose-limiting toxicity (DLT) will be defined as an adverse event attributed (definitely, probably, possibly) in the first or second cycle for patients enrolled to Dose Levels -1 and 0 and in the first cycle only for patients enrolled to Dose Levels 1 and 2.

    We are reporting the number of DLTs


  • Percentage of Patients Who Have at Least a Confirmed Very Good Partial Response (Phase II) [ Time Frame: Following the first 4 cycles of treatment (28 day cycles) ] [ Designated as safety issue: No ]

    The proportion of patients who have at least a confirmed very good partial response will be calculated by taking the number of patients with a very good partial response or a complete response divided by the total number of patients.

    A complete response is defined as:

    • Negative immunofixation of the serum and urine
    • If at on study, only the measurable non-bone marrow parameter was FLC, normalization of FLC ratio
    • < 5% plasma cells in bone marrow
    • Disappearance of any soft tissue plasmacytomas

    A very good partial response is defined as:

    • Serum and urine M-component detectable by immunofixation but not on electrophoresis or
    • If at on study, serum measurable, ≥ 90% or greater reduction in serum Mcomponent
    • Urine M-component <100 mg per 24 hour


Secondary Outcome Measures:
  • Progression-free Survival (Phase II) [ Time Frame: From baseline to progression or death up to 3 years ] [ Designated as safety issue: No ]

    PFS was defined as the time from registration to progression or death due to any cause. Progression was defined as any one or more of the following:

    • Increase of 25% from lowest confirmed response in: Serum M-component (absolute increase must be ≥ 0.5 g/dl)c Urine M-component (absolute increase must be ≥ 200 mg/24 hour) If at on study, only the measurable non-bone marrow parameter was FLC, the difference between involved and uninvolved FLC levels (absolute increase must be >10 mg/dl) Bone marrow plasma cell percentage (absolute % must be 10%)d Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas

    • Development of hypercalcemia (corrected serum calcium >11.5 mg/dl) that can be attributed solely to the plasma cell proliferative disorder


  • Time to Treatment Failure [ Time Frame: From baseline to end of active treatment ] [ Designated as safety issue: Yes ]
    The time from the date of registration to the date at which the patient is removed from treatment due to progression, adverse events, or refusal. If the patient is considered to be a major treatment violation or is taken off study as a non-protocol failure, the patient will be censored on the date they were removed from treatment. The distribution of time to treatment failure will be estimated using the method of Kaplan-Meier

  • Stem Cell Collection and Engraftment (Phase II) [ Time Frame: Following the first 4 courses of treatment ] [ Designated as safety issue: No ]
    For patients going on to stem cell collection, the total number of CD34 positive cells collected per collection, days to platelets over 20,000 without transfusion and ANC over 1000 will be recorded. If a patient fails to collect adequate stem cells for transplant, this will be recorded as such. The number of patients with successful stem cell mobilization are reported.

  • Complete Response (Phase II) [ Time Frame: Following the first 4 courses of treatment ] [ Designated as safety issue: No ]
    In patients continuing beyond 4 cycles the ability to induce complete response will be evaluated at completion of planned therapy.

  • Survival Time (Phase II) [ Time Frame: From baseline to death ] [ Designated as safety issue: No ]
    Survival time is defined as the time from registration to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier

  • Progression Free Survival (12 Month) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Progression-free survival time is defined as the time from registration to the earliest date of documentation of disease progression. If a patient dies without a documentation of disease progression the patient will be considered to have had disease progression at the time of their death. If the patient is declared to be a major treatment violation, the patient will be censored on the date the treatment violation was declared to have occurred. In the case of a patient starting treatment and then never returning for any evaluations, the patient will be censored for progression 1 day post-registration. This is reported as the percentage of patients alive and progression free at the 12 month mark.

  • Progession Free Survival (24 Month) [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    Progression-free survival time is defined as the time from registration to the earliest date of documentation of disease progression. If a patient dies without a documentation of disease progression the patient will be considered to have had disease progression at the time of their death. If the patient is declared to be a major treatment violation, the patient will be censored on the date the treatment violation was declared to have occurred. In the case of a patient starting treatment and then never returning for any evaluations, the patient will be censored for progression 1 day post-registration. This is reported as the percentage of patients alive and progression free at the 24 month mark.

  • Overall Survival (12 Month) [ Time Frame: From baseline to death ] [ Designated as safety issue: No ]
    12 Month Overall survival is defined as the proportion of patients to still be alive after 12 months.

  • Overall Survival (24 Month) [ Time Frame: From baseline to death ] [ Designated as safety issue: No ]
    24 Month Overall survival is defined as the proportion of patients to still be alive after 24 months.


Enrollment: 64
Study Start Date: March 2010
Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I
Patients receive carfilzomib IV on days 1, 2, 8, 9, 15, and 16; oral cyclophosphamide on days 1, 8, and 15; oral dexamethasone on days 1, 8, 15, and 22; and oral thalidomide on days 1-28.
Drug: carfilzomib
Given IV
Other Name: PR-171
Drug: cyclophosphamide
Given orally
Other Names:
  • CPM
  • CTX
  • Cytoxan
  • Endoxan
  • Endoxana
  • Enduxan
Drug: thalidomide
Given orally
Other Names:
  • alpha-phthalimidoglutarimide
  • Contergan
  • Kevadon
  • Synovir
  • THAL
  • Thalomid
Drug: dexamethasone
Given orally
Other Names:
  • Aeroseb-Dex
  • Decaderm
  • Decadron
  • Decaspray
  • DM
  • DXM

Detailed Description:

PRIMARY OBJECTIVES:

I. To establish the maximum tolerated dose of carfilzomib given in combination with oral cyclophosphamide and thalidomide and dexamethasone. (Phase I) II. In newly diagnosed myeloma to evaluate the response rate (CR, nCR, and VGPR) to carfilzomib given in combination with oral cyclophosphamide and thalidomide and dexamethasone after four 28 day cycles. (Phase II)

SECONDARY OBJECTIVES:

I. Determine the overall response rate (CR, nCR, PR) after 4, 8, 12 cycles. II. Determine the duration of progression-free and overall survival for patients receiving this regimen.

III. To evaluate the incidence of toxicities for this regimen. IV. To evaluate the ability to successfully collect peripheral blood stem cells following four months of combination therapy.

OUTLINE: This is a phase I, dose escalation study of carfilzomib followed by a phase II study.

Patients receive carfilzomib IV on days 1, 2, 8, 9, 15, and 16; oral cyclophosphamide on days 1, 8, and 15; oral dexamethasone on days 1, 8, 15, and 22; and oral thalidomide on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed at 3 months, then every 3 months for 1 year, and then every 6 months for up to 3 years.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion

  • Creatinine =< 2 mg/dL
  • Calculated Creatinine Clearance >= 30 mL/min
  • Total Bilirubin =< 2.0 mg/dL
  • Alkaline Phosphatase =< 3 x ULN
  • ALT =< 3 x ULN
  • Absolute neutrophil count >= 1000/uL
  • Platelet >= 75000/uL
  • Hemoglobin >= 8.0 g/dL
  • Untreated symptomatic myeloma: Prior non-systemic therapy for the treatment of solitary plasmacytoma is permitted, but >= 1 month should have elapsed from the last day of radiation; prior therapy with clarithromycin, DHEA, anakinra, pamidronate or zoledronic acid is permitted; any additional agents not listed must be approved by the Principal Investigator
  • Prior high dose corticosteroid therapy for twelve days (480 mg total dose) or less is permitted for emergent complications from newly diagnosed multiple myeloma
  • Measurable disease of multiple myeloma, as defined by at least ONE of the following:
  • Serum monoclonal protein >= 1.0 g by protein electrophoresis
  • OR > 200 mg of monoclonal protein in the urine on 24 hour electrophoresis
  • OR serum immunoglobulin free light chain >= 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio; OR monoclonal bone marrow plasmacytosis >= 30% (evaluable disease)
  • ECOG performance status (PS) 0, 1, 2; ECOG PS of 3 will be allowed if secondary to pain in the opinion of the Investigator
  • Willingness and able to provide informed written consent
  • Negative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
  • Willingness to return to Mayo Clinic enrolling institution for follow-up

Exclusion

  • MGUS or smoldering myeloma
  • Peripheral sensory neuropathy >= Grade 2 as defined by CTEP Active Version of the CTCAE
  • Active malignancy with the exception of non melanoma skin cancer or in situ cervical or breast cancer
  • Pregnant women or women of reproductive ability who are unwilling to use effective contraception
  • Nursing women
  • Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 4 weeks after stopping treatment
  • Known hypersensitivity, allergy or inability to tolerate any of the agents employed
  • Active, uncontrolled infection
  • Severe cardiac comorbidity
  • New York Heart Association Class III or IV Heart Failure
  • Recent history of myocardial infarction in the six months prior to registration
  • Uncontrolled angina or electrocardiographic evidence of acute ischemia
  • Severe uncontrolled ventricular arrhythmias or electrocardiographic evidence of active conduction system abnormalities
  • Cardiac amyloidosis with hypotension (systolic BP less than 100 mmHg)
  • Other concurrent chemotherapy, radiotherapy, or any ancillary therapy considered investigational; NOTE: Bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatment
  • The following medications are not permitted during the trial: any other investigational treatment; any cytotoxic chemotherapy; any other systemic anti-neoplastic therapy including, but not limited to, immunotherapy, hormonal therapy, or monoclonal antibody therapy
  • Palliative radiation therapy is permitted if clinically indicated and not indicative of progressive disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01057225

Locations
United States, Arizona
Mayo Clinic in Arizona
Scottsdale, Arizona, United States, 85259
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425-6350
Sponsors and Collaborators
Mayo Clinic
Investigators
Study Chair: Joseph R. Mikhael, M.D. Mayo Clinic
  More Information

Responsible Party: Mayo Clinic
ClinicalTrials.gov Identifier: NCT01057225     History of Changes
Other Study ID Numbers: MC0982  NCI-2009-01699  PT-171-502  09-004091  MC0982 
Study First Received: January 26, 2010
Results First Received: August 2, 2016
Last Updated: September 26, 2016
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone acetate
Dexamethasone
Dexamethasone 21-phosphate
Cyclophosphamide
Thalidomide
BB 1101
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal

ClinicalTrials.gov processed this record on December 09, 2016